A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers (Q85944296)
Jump to navigation
Jump to search
scientific article published on 11 November 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers |
scientific article published on 11 November 2014 |
Statements
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers (English)
Jan H M Schellens
Didier Meulendijks
Lilian L Siu
Vaios Karanikas
Derek J Jonker
Aaron R Hansen
Mary E Simcox
Kathleen J Schostack
Dean Bottino
Hua Zhong
Markus Roessler
Suzana M Vega-Harring
Tiantom Jarutat
David Geho
Ka Wang
Mark DeMario
Glenwood D Goss
11 November 2014